Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 145040
Corporate User License Price USD 6000
Corporate User License Price INR 435120
Site License Price USD 4000
Site License Price INR 290080
Request a Quote

Report Title

Acromegaly-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Acromegaly-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Acromegaly-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Acromegaly-Pipeline Review, H1 2017



Executive Summary

Acromegaly-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly-Pipeline Review, H1 2017, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape.

Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acromegaly-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 3, 8 and 3 respectively.

Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Acromegaly (Hormonal Disorders).

The pipeline guide reviews pipeline therapeutics for Acromegaly (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Acromegaly (Hormonal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Acromegaly (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Acromegaly (Hormonal Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Acromegaly (Hormonal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Acromegaly (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Acromegaly-Overview

Acromegaly-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Acromegaly-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acromegaly-Companies Involved in Therapeutics Development

Aegis Therapeutics LLC

Amryt Pharma plc

Antisense Therapeutics Ltd

Chiasma Inc

Crinetics Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Dauntless Pharmaceuticals Inc

DexTech Medical AB

Foresee Pharmaceuticals LLC

Glide Pharmaceutical Technologies Ltd

Ionis Pharmaceuticals Inc

Ipsen SA

Italfarmaco SpA

Midatech Pharma Plc

Novartis AG

Peptron Inc

Silence Therapeutics Plc

Strongbridge Biopharma plc

Sun Pharma Advanced Research Company Ltd

Acromegaly-Drug Profiles

Antisense Oligonucleotide to Inhibit Growth Hormone Receptor for Acromegaly-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

atesidorsen sodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIM-23B065-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-GHRLRx-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ITF-2984-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

L-779976-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanreotide SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate long acting-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Somadex-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SXN-101959-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Acromegaly-Dormant Projects

Acromegaly-Discontinued Products

Acromegaly-Product Development Milestones

Featured News & Press Releases

Mar 10, 2017: Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility

Feb 16, 2017: Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery

Feb 06, 2017: Amryt Pharma Announces positive pre-clinical study results for drug compound with potential to treat acromegaly, AP102

Dec 02, 2016: Amryt Pharma provides update on AP-102

Nov 07, 2016: FDA Orphan Drug Designation Received for Drug Compound with Potential to Treat Acromegaly

Sep 22, 2016: Aegis Awarded Patent for Non-Invasive Nasal Octreotide Formulation

Jul 27, 2016: Positive Results Achieved from Interim Analysis of ATL1103 Higher Dose Study

Jul 13, 2016: ATL1103 Patent Update

Jun 28, 2016: Glide Technologies announces successful clinical proof-of-concept study

Jun 14, 2016: Chiasma Announces Corporate Restructuring Plan and Provides Regulatory Update Regarding Mycapssa

Jun 01, 2016: Antisense provides update on ATL1103 clinical trials

May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology

May 19, 2016: Glide Technologies Initiates Clinical Proof-of-Concept Study with Novel Octreotide Solid Dose Formulation Delivered via Needle-Free SDI

May 12, 2016: Orphan Drug designation from FDA for ATL1103 in Acromegaly

Apr 26, 2016: Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Acromegaly, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Acromegaly, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Acromegaly-Pipeline by Aegis Therapeutics LLC, H1 2017

Acromegaly-Pipeline by Amryt Pharma plc, H1 2017

Acromegaly-Pipeline by Antisense Therapeutics Ltd, H1 2017

Acromegaly-Pipeline by Chiasma Inc, H1 2017

Acromegaly-Pipeline by Crinetics Pharmaceuticals Inc, H1 2017

Acromegaly-Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017

Acromegaly-Pipeline by Dauntless Pharmaceuticals Inc, H1 2017

Acromegaly-Pipeline by DexTech Medical AB, H1 2017

Acromegaly-Pipeline by Foresee Pharmaceuticals LLC, H1 2017

Acromegaly-Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017

Acromegaly-Pipeline by Ionis Pharmaceuticals Inc, H1 2017

Acromegaly-Pipeline by Ipsen SA, H1 2017

Acromegaly-Pipeline by Italfarmaco SpA, H1 2017

Acromegaly-Pipeline by Midatech Pharma Plc, H1 2017

Acromegaly-Pipeline by Novartis AG, H1 2017

Acromegaly-Pipeline by Peptron Inc, H1 2017

Acromegaly-Pipeline by Silence Therapeutics Plc, H1 2017

Acromegaly-Pipeline by Strongbridge Biopharma plc, H1 2017

Acromegaly-Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Acromegaly-Dormant Projects, H1 2017

Acromegaly-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Aegis Therapeutics LLC, Amryt Pharma plc, Antisense Therapeutics Ltd, Chiasma Inc, Crinetics Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Dauntless Pharmaceuticals Inc, DexTech Medical AB, Foresee Pharmaceuticals LLC, Glide Pharmaceutical Technologies Ltd, Ionis Pharmaceuticals Inc, Ipsen SA, Italfarmaco SpA, Midatech Pharma Plc, Novartis AG, Peptron Inc, Silence Therapeutics Plc, Strongbridge Biopharma plc, Sun Pharma Advanced Research Company Ltd


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand